Showing results (241-250 of 453) with videos related to

Sort By:
Pageof 46
Emerging Infectious Diseases|December 6, 2024
Ongoing Evolution of Middle East Respiratory Syndrome Coronavirus, Saudi Arabia, 2023-2024Ahmed M Hassan, Barbara Mühlemann, Tagreed L Al-Subhi, et al.
Journal for Immunotherapy of Cancer|July 28, 2021
Author response to Cunha et alRivka R Colen, Christian Rolfo, Murat Ak, et al.
JCO Precision Oncology|July 14, 2022
Longitudinal Monitoring of Circulating Tumor DNA to Predict Treatment Outcomes in Advanced CancersMohamed A Gouda, Helen J Huang, Sarina A Piha-Paul, et al.
Frontiers in Pharmacology|April 12, 2021
Identification of Plitidepsin as Potent Inhibitor of SARS-CoV-2-Induced Cytopathic Effect After a Drug Repurposing ScreenJordi Rodon, Jordana Muñoz-Basagoiti, Daniel Perez-Zsolt, et al.
Journal for Immunotherapy of Cancer|April 14, 2021
Radiomics analysis for predicting pembrolizumab response in patients with advanced rare cancersRivka R Colen, Christian Rolfo, Murat Ak, et al.
Scientific Reports|November 19, 2023
Efficacy of futibatinib, an irreversible fibroblast growth factor receptor inhibitor, in FGFR-altered breast cancerTurcin Saridogan, Argun Akcakanat, Ming Zhao, et al.
Cancer Chemotherapy and Pharmacology|September 17, 2008
Phase I study of cetuximab, erlotinib, and bevacizumab in patients with advanced solid tumorsChia-Chi Lin, Emiliano Calvo, Kyriakos P Papadopoulos, et al.
Radiation Research|August 8, 2022
Targeted Inhibition of DNA-PKcs, ATM, ATR, PARP, and Rad51 Modulate Response to X Rays and ProtonsScott J Bright, David B Flint, David K J Martinus, et al.
Drug Discovery Today|December 8, 2009
Can molecular biomarker-based patient selection in Phase I trials accelerate anticancer drug development?Craig P Carden, Debashis Sarker, Sophie Postel-Vinay, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 23, 2025
Intratumoral or Subcutaneous MK-2118, a Noncyclic Dinucleotide STING Agonist, with or without Pembrolizumab, for Advanced or Metastatic Solid Tumors or LymphomasJason J Luke, Randy F Sweis, J Randolph Hecht, et al.
Pageof 46